S. Murdande

发表

Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement

Ravi M Shanker, Michael J Pikal, M. Pikal, 2011, Pharmaceutical development and technology.

Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?

M. Pikal, R. Shanker, R. Bogner, 2011, Journal of pharmaceutical sciences.

Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement

M. Pikal, R. Shanker, R. Bogner, 2011, Pharmaceutical development and technology.

Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase.

Eliot Sugarman, Zhengrong Zhao, Wei Song, 2012, Journal of medicinal chemistry.

Development of a self-emulsifying formulation that reduces the food effect for torcetrapib.

S. Murdande, M E Perlman, S B Murdande, 2008, International journal of pharmaceutics.

Solubility Advantage of Amorphous Pharmaceuticals: II. Application of Quantitative Thermodynamic Relationships for Prediction of Solubility Enhancement in Structurally Diverse Insoluble Pharmaceuticals

Michael J. Pikal, M. Pikal, R. Shanker, 2010, Pharmaceutical Research.

Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.

Ravi M Shanker, Michael J Pikal, M. Pikal, 2010, Journal of pharmaceutical sciences.

Sustained‐release Morphine for Epidural Analgesia in Rats

A. Gruber, S Kim, S. Murdande, 1996, Anesthesiology.

Impact of nanosizing on solubility and dissolution rate of poorly soluble pharmaceuticals.

R. Dave, S. Murdande, D. Shah, 2015, Journal of pharmaceutical sciences.

Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2.

R. McPherson, L. Tong, E. Marr, 2010, Bioorganic & medicinal chemistry letters.

Influence of spray drying and dispersing agent on surface and dissolution properties of griseofulvin micro and nanocrystals

R. Dave, S. Murdande, D. Shah, 2016, Drug development and industrial pharmacy.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

A Review: Pharmaceutical and Pharmacokinetic Aspect of Nanocrystalline Suspensions.

R. Dave, S. Murdande, D. Shah, 2016, Journal of pharmaceutical sciences.